Avatrombopag-d8 hydrochloride

Cat. No.: IBDI-435719

Avatrombopag-d8 (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A.

Product Details

Target	Thrombopoietin Receptor
Molecular Weight	694.16
Synonyms	AKR-501-d8 (hydrochloride), E5501-d8 (hydrochloride), YM477-d8 (hydrochloride)
SMILES	O=C(C1CCN(C2=NC=C(C(NC3=NC(C4=CC(Cl)=CS4)=C(N5C([2H])([2H])C([2H])([2H])N(C6CCCCC6)C([2H])([2H])C5([2H])[2H])S3)=O)C=C2Cl)CC1)O.Cl

Storage & Handling

Shipping	Room temperature in continental US. May vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Regulatory Status	This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use.